Keeping Those Little Blue Pill Sales Up

It looks like Pfizer's (NYSE: PFE  ) Viagra won't have any little blue generic competition for a while. During a court case with Teva Pharmaceutical (Nasdaq: TEVA  ) , Pfizer successfully defended its patent to keep generic competition at bay until October 2019.

The composition of matter patent on Viagra's active ingredient expires next year, but the pharma giant applied for a method of use patent to cover using the drug to treat erectile dysfunction. That type of patent is often hard to defend because generic-drug makers are able to argue that testing the drug for that type of use was obvious, and obvious ideas aren't patentable.

But using Viagra as an erectile dysfunction drug wasn't so obvious. The drug was originally developed as Revatio for high blood pressure, but Pfizer realized that it also helped with erectile dysfunction.

With sales of about $1 billion in the U.S., this is a big win even for a company the size of Pfizer. Including an additional billion in international sales, Viagra makes up about 3% of Pfizer's current revenue. With the loss of Lipitor, revenue is headed lower. Viagra is likely one of Pfizer's higher-margin products, so the contribution to the bottom line is even more substantial.

Ironically, Viagra's competition in the erectile dysfunction space -- Eli Lilly's (NYSE: LLY  ) Cialis and Bayer and GlaxoSmithKline's (NYSE: GSK  ) Levitra -- will also benefit from Pfizer fighting off the generic competition. Patients often switch medication when cheap generics become available. Pfizer's Lipitor saw that happen when Merck's (NYSE: MRK  ) Zocor went generic.

The biggest beneficiary could be VIVUS (Nasdaq: VVUS  ) , which has a new erectile dysfunction drug currently under review by the FDA. It's going to be hard enough competing with the big boys; launching against a cheap generic would have made things extremely difficult.

Keep it up, Pfizer. Keep it up.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Click here to see his holdings and a short bio. The Motley Fool owns shares of Teva and GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline, Teva, and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1539816, ~/Articles/ArticleHandler.aspx, 8/22/2014 7:19:11 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement